MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced that it will present at the Morgan Stanley Global
Healthcare Conference at the Grand Hyatt Hotel in New York City on
Wednesday, September 14, 2016. Management is scheduled to present
at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may
be accessed by visiting the Investors page of AtriCure’s corporate
website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 75,000 implanted to date.
For more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160818005783/en/
Source: AtriCure, Inc.
Andy Wade, 513-755-4564
President and Chief Financial Officer
Lynn Pieper Lewis,